Percutaneous Closure of Medium and Large PDAs Using Amplatzer Duct Occluder (ADO) I and II in Infant

(/)
(http://hmpholdings.advertserve.com/servlet/click/zone?
zid=96&cid=1851&mid=1628&pid=0&sid=32&uuid=9e8924e9b27e3e60b4b9b7103f27fd8a&ip=36.76.158.152&default=false&random=34709902&timestamp=20150707053134&te
closure-medium-and-large-pdas-using-amplatzer-duct-occluder-ado-i-and-ii&redirect=http%3A%2F%2Fwww.amptheclimeeting.com)
zid=96&cid=1851&mid=1628&pid=0&sid=32&uuid=cfbe2f1b82dc92754730425cd758321f&ip=36.76.158.152&default=false&random=91712747&timestamp=20150707052540&te
zid=80&cid=1846&mid=1805&pid=0&sid=32&uuid=9e8924e9b27e3e60b4b9b7103f27fd8a&ip=36.76.158.152&default=false&random=36436218&timestamp=20150707053134&te
closure-medium-and-large-pdas-using-amplatzer-duct-occluder-ado-i-and-ii&redirect=http%3A%2F%2Fwww.clidiagnosticsandinterventions.com%2F)
Percutaneous Closure of Medium and Large PDAs Using Amplatzer Duct Occluder (ADO) I and II in
Infants: Safety and Efficacy
Thursday, 11/01/12 | 8680 reads
Author(s): Rasha I. Ammar, MD and Ranya A. Hegazy, MD
Issue Number:
Volume 24 - Issue 11 - November 2012 (http://www.invasivecardiology.com/issue/3602)
Abstract: Background. The use of the Amplatzer duct occluder (ADO; AGA Medical Corporation) is well established and reported in children and adults, but there are only
occasional reports on use in symptomatic infants. Methods and Results. Between March 2009 and January 2011, a group of 47 infants less than 2 years of age with
symptomatic patent ductus arteriosus (PDA) was treated using ADO I and II devices. Patients were divided into infants less than 1 year old (group A; n = 28/47; 59.6%) and
children between 1 and 2 years old (group B; n = 19/47; 40.4%). Physical examinations and echocardiograms were performed before the procedure and at follow-up (3, 6,
and 12 months). Mean age was 5.3 2.3 months for group A and 12.6 1.7 months for group B. Mean weight at closure was 4.8 1.9 kg for group A and 7.3 2.1 kg for
group B. ADO I was deployed in 19/28 of group A (67.9%) and 16/19 of group B (84.2%). ADO II was used in 9/28 of group A (32.1%) and 3/19 of group B (15.8%). No
residual shunt at the end of the procedure was detected by angiography in any of the cases closed with ADO I and only 3/12 (25%) closed with ADO II showed a minimal
residual flow. No mortality or major complications occurred. Six months after closure, weight gain, control of respiratory infections, and regression of left ventricular
dilatation with improved systolic function were observed. Conclusions. Percutaneous closure of moderate to large PDAs using ADO I and II devices in infants and children
younger than 2 years of age is safe and eective.
J INVASIVE CARDIOL 2012(11);24:579-582
Key words: Amplatzer duct occluder, patent ductus arteriosus
_______________________________________________
Percutaneous closure of patent ductus arteriosus (PDA) is a well-established procedure for the vast majority of pediatric patients. Since the first percutaneous closure of
PDA by Porstmann,1,2 various researchers have described several techniques and occluders for non-surgical closure.3-7
The degree of successful deployment is variable and the incidence of residual shunting is reported to be between 3% and 38%.1-9 In 1998, Masura et al10 published the
first series of cases of percutaneous closure of the arterial duct using the new Amplatzer device, which was especially designed for medium to large ducts. The Amplatzer
duct occluder (ADO; AGA Medical Corporation) has been widely used in many centers, with less incidence of residual leak, embolization, and left pulmonary artery
stenosis.11,12 An important advantage is that it has a small-caliber detachment system, and so can be used in young children. Some diculties in using the ADO for
occlusion of a large ductus in infants have been reported13,14 and few studies have investigated their usefulness in children under 1 year of age. In this study, we describe
our experience, immediate and mid-term results with the use of the ADO to close moderate to large PDAs in a pediatric population of infants and children <2 years of age.
Methods
Between March 2009 and January 2011, a cohort of 47 infants and children less than 2 years of age with PDAs were percutaneously closed using ADO I and II devices.
Patients were divided into infants less than 1 year (group A; n = 28/47; 59.6%) and children between 1 and 2 years (group B; n = 19/47; 40.4%). The mean ductal size was
3.8 2.4 mm as estimated echocardiographically. Both groups suered congestive heart failure, moderate to severe left ventricular (LV) dilatation and compromise of LV
systolic function. Failure to thrive and recurrent bronchopneumonias were prominent features in the entire study group.
All patients underwent clinical evaluation, chest x-ray and echocardiography upon admission. The left ventricular end-diastolic dimension (LVEDD), left atrial diameter (LAD),
estimated systolic pulmonary artery pressure (ESPAP), and LV fractional shortening (FS%) were assessed using detailed transthoracic echocardiography (TTE) including 2dimensional (2D), M-mode, and Doppler assessments. Ductal size, morphology, and transductal pressure gradient were evaluated. Informed consent was obtained from the
parents of each patient.
The selection criteria were as follows: age 2 years, weight >3.5 kg, and clinical and echocardiographic findings of PDA with a minimum diameter of 2 mm. The clinical
indications for PDA closure were as follows: heart failure, failure to thrive, recurrent respiratory infections, and dilatation of the left side as evaluated by 2D echocardiogram.
Recurrent respiratory infections were defined as more than 6 events during a 6 month period and failure to thrive was defined according to Ramos-Galvan,15 as a child
younger than 2 years whose weight crosses two major percentiles downward in a standardized growth grid using the 90th, 75th, 50th, 25th, 10th, and 5th percentiles as the
major percentiles. All patients had signs of significant left to right shunting through the PDA with left atrial enlargement and ventricular volume overload on 2D
echocardiography.
The form of the arterial duct was determined according to the classification of Krichenko.16
Device selection and implantation protocol. The ADO implantation protocol has been described in previous communications.10,17-19 The procedure was conducted
under general anesthesia, with biplane fluoroscopy. The femoral artery and vein were catheterized and 100 U/kg sodium heparin and cefotaxime 100 mg/kg single dose
were administered. After recording pulmonary and systemic pressures, an aortogram was conducted in lateral and right anterior oblique projections to define duct
morphology and size. The largest and smallest diameters of the ductus were measured (the larger measurement being at the aortic side and the smaller being at the
pulmonary side); the diameter of the aortic ampulla and the length of the PDA were also recorded.
Anterograde catheterization was performed in all cases. Devices at least 1-2 mm larger than the minimum diameter of the PDA were selected. Generally, a 5-6 Fr AGA
sheath (AGA Medical Corporation) was used to deliver the device. The device, which when attached to the tip of the release cable and withdrawn into the loader, was
introduced through the sheath to the descending aorta. Once in place, the retention disk was opened and positioned in the aortic ampulla of the duct.
Subsequently, the rest of the sheath was withdrawn toward the pulmonary trunk, positioning the tubular part of the Amplatzer device within the duct. With the device still
anchored to the release cable, an aortogram was performed and when good placement was verified, the device was detached; 10 minutes after ADO implantation,
angiography of the descending aorta was conducted to detect any residual shunt.
The ADO I is a cone-shaped device, 7 mm in length, made of a 0.004 nitinol wire mesh. A 2 mm retention skirt extends radially around the distal part of the device, assuring
secure fixation in the mouth of the PDA. Prostheses are available in sizes ranging from 6-4 to 14-12 mm at increments of 2 mm. The device is attached by a recessed microscrew to a 0.038 delivery cable made of stainless steel; it is delivered through a 5 to 6 Fr long sheath. For introduction into the delivery sheath, the device is pulled into a
special Teflon loader.
The ADO II diers in being composed of two discs and a connecting waist. It is available in waist sizes (3, 4, 5, and 6) in two lengths for each size (4 and 6 mm).
Following the procedure, 3 doses of antibiotics were given. Patients were discharged the next day after clinical evaluation. Prophylaxis for bacterial endocarditis was
indicated for 6 months following the procedure.16
Follow-up protocol. Chest x-ray and TTE were conducted at 24 hours to evaluate the shape and position of the device. Color Doppler ultrasound was used to detect and
quantify any residual shunt.
The severity of leakage as assessed by color Doppler was arbitrarily defined as follows:18 trivial, <1 mm diameter; mild, 1-2 mm diameter; or moderate, >2 mm diameter at
the site of leak onset. Pulsed and continuous-wave Doppler ultrasound were used to determine flow and velocity patterns in the descending aorta and pulmonary artery to
rule out obstruction. Follow-up with TTE was conducted at 1, 3, 6, and 12 months after implantation. Major and minor complications related to device implantation were
analyzed and described at each assessment. Major complications included: procedure-associated mortality; femoral artery lesion; blood loss 5% of the estimated blood
volume; migration of the device to the lumen of the pulmonary branch or descending aorta. Minor complications included protrusion of the device into the bed of the
pulmonary branch or descending aorta causing turbulent flow (2-2.5 m/s) across the origin of the left pulmonary artery or descending aorta, and was considered to be
acquired stenosis.
Statistical analysis. Continuous variables were expressed as mean standard deviation or as medians and intervals; discrete variables are expressed as absolute values
and percentages. The Students t-test was used to compare continuous variables, and the Fishers exact test was used for comparison of discrete variables. P-value less
than .05 was considered significant.
Results
The study included 31 girls (66%) and 16 boys (34%). Their mean age was 5.3 2.3 months for group A and 12.6 1.7 months for group B. Mean weight at closure was 4.8
1.3 kg for group A and 7.3 2.1 kg for group B.
(/files/Ammar1.png)A total of 44/47 of the study group (93.6%) had symptoms of heart failure and failure to thrive, of whom 33/43 (77%) had cardiomegaly
on chest radiography and echocardiography and 21/47 (44.7%) had recurrent respiratory tract infections. Three (6.4%) were asymptomatic, all in group B.
PDA presented as an isolated lesion in 41/47 of patients (87%), where a patent foramen ovale was not included in the definition of associated lesions.
Associated heart lesions were seen in 6/47 (13%): 4 cases of moderate to severe valvular pulmonary stenosis, and 2 cases of associated complete heart
block (Table 1).
On reviewing the TTE data of all cases, the mean ductal size was 3.8 2.4 mm for group A and 4.2 1.9 mm for group B. Mean LVEDD was 32.4 4.7 mm and 36.3 4.9
mm for groups A and B, respectively. Most of the patients had Doppler evidence of pulmonary hypertension with a mean ESPAP of 57.2 6.6 mm Hg for Group A and 54.9
7.3 mm Hg for group B. Comparing these data between the two groups revealed no statistically significant dierences (P>.05). Data illustrated in Table 2.
The minimum and maximum diameters of the arterial duct, measured angiographically, were 3.7 1.1 mm and 8.8 1.9 mm for group A and 4.2 0.9 mm and 10.2 2.4
mm for group B, respectively. Device implantation was successful in all 47 patients (100%). The duct morphologies according to the Krichenko classification16 were as
follows: type A in 44/47 patients (94%); type B in 1 patient (2%); and type C in 2 patients (4%).
Pulmonary hypertension was observed in all patients. The mean procedure time was 59 3.7 minutes and 61.3 7.4 minutes for groups A and B, respectively, with no
significant dierences between them. ADO I was deployed in 19/28 group A patients (67.9%) and 16/19 group B patients (84.2%). The sizes of the implanted devices were
as follows: 5/4 in 1 patient; 6/4 in 18 patients; 8/6 in 14 patients; and 10/8 in 2 patients. ADO II was used in 9/28 group A patients (32.1%) and 3/19 group B patients
(15.8%). ADO II size 5/4 mm was used in 9 cases and 5/6 mm in 3 cases. No residual shunt at the end of procedure was detected by angiography in any of the cases
closed with ADO I. A total of 3/12 cases (25%) closed with ADO II revealed minimal intraprosthetic flow that disappeared at 1-month follow-up (Table 1).
There was no procedure-associated mortality. Immediate occlusion, confirmed by angiography, was achieved in 44/47 patients (93.6%); 3/47 patients (6.4%) showed trivial
postprocedural intraprosthetic leak. After device implantation, no patient showed a pressure gradient between the ascending and descending aorta, or between the left
pulmonary artery and pulmonary trunk.
During the procedure and at the endpoint of the study, no major complications occurred. Minor complications occurred in 4/28 patients (14.3%) in group A and 2/19
patients (10.5%) in group B, in the form of peripheral vascular complications such as loin hematoma and venous thrombosis which were managed successfully with no
long-term sequelae. A total of 2/47 cases (4.3%) had mild LPA stenosis with a Doppler systolic gradient of 16 mm Hg in 1 case and 19 mm Hg in the other. One/47 cases
(2%) had intra-aortic bulge of the device, with no associated systolic gradient across the descending aorta. These 3 cases were in group A, less than 6 months of age and
<5 kg in weight.
(/files/Ammar2.png)At 6- and 12-month follow-up after closure, weight gain, control of respiratory infections, and regression of LV dilatation with
normalization of the systolic function were observed. The echocardiographic data and weight before and at 6-month follow-up are shown in Table 2.
Discussion
In this study, the results of using the ADO for the percutaneous closure of PDA in children under 2 years of age are presented. The immediate occlusion rate was 93.6% and
6.4% had trivial residual leak that disappeared after 1 month. Occlusion rate was 100% when using an ADO I device and 88% when ADO II was used, as a residual shunt
was observed in 3/12 cases (12%) and disappeared at 1-month follow-up. An occlusion rate of 96% was obtained at 3-month follow-up in many studies.10-12,15-18
There are few studies on the use of ADO in children under 1 year of age or weighing 10 kg.11,16,19-21 The mean age and weight in our study group was 5.3 months and 4.8
kg for group A and 12.6 months and 7.3 kg for group B. The improvements made to the Amplatzer occluder taking into account the small size of the release systems (5-7
Fr) and the conic shape of the prosthesis facilitate their use in relatively large ducts in low-weight, premature babies under 1 year of age.19-21,22 Previous studies have
recommended that the ADO should not be used in patients weighing <5 kg due to observed technical diculties,11,17,20 which may still be observed in infants weighing 5
kg.20 In this study, we encountered no technical diculties with implantation, probably because 94% of our study population had Krichenko type A duct morphology.
PDA may be an isolated anomaly or associated with some other cardiac anomalies.21,22 In this study, 6/47 cases (13%) had an associated cardiac anomaly: 4 cases of
moderate to severe valvular pulmonary stenosis, and 2 cases of associated complete heart block. Infants with a large ductus are usually symptomatic with tachypnea,
tachycardia, and diculty in feeding. Failure to thrive and recurrent respiratory tract infections are also quite common. Early closure is generally required to relieve the
symptoms. Recurrent chest infections were documented in 44.7% of cases. A total of 93.6% of our cases had symptoms of heart failure and failure to thrive and were
receiving antifailure medications such as digoxin, captopril, and frusemide, which were the basis for the early duct closure.
Procedure failure has been reported in many studies.10,13 Fischer et al13 mentioned technical diculties in 9 out of 12 patients. In this study, we had no device implantation
failures.
Although coil closure is eective, procedural failure is not uncommon in infants with a large ductus, and using large and multiple coils in infants frequently results in left
pulmonary artery stenosis.2,5-7,9,23 Left pulmonary artery stenosis is not uncommon following deployment of ADO, but is usually mild (Vmax <2.5 m/s).10-14 Avoiding using
an excessively over-sized device in infants may decrease the incidence of this complication. Coarctation of the aorta following implantation of an ADO is not rare,10-12,24 but
occurs mostly in young infants, in whom an excessively oversized device is implanted, resulting in protrusion of the retention flange into the aorta. None of the patients
above the age of 1 year showed these complications. However, in the patients <1 year, mild LPA stenosis was noted in 2 patients and intra-aortic bulge was noted in 1
patient. ADO I was deployed for closure in these 3 cases; on the other hand, no similar findings were encountered in any of the cases where ADO II was deployed.
Moreover, all these patients were <6 months and 5 kg, hence presuming a link to low body weight since these complications are observed with greater frequency in infants
and young children with low body weight, an eect related to small vessel calibers and relatively large delivery sheaths.19,20,22 In most patients, aortic obstruction is
clinically non-significant and is only detected by echocardiographic study,24 as is the case in the present work.
None of our patients died. Procedure-related mortality is generally rare (12 and only immediate deaths have been reported).11,12,21-27 Procedure-associated complications
have been described in the dierent age groups, and these are relatively major in patients <1 year of age or weighing <10 kg.19-21 No major complications were
encountered in any of our study group. Faella et al12 report an 8.2% incidence of complications in children aged 1 year or less, compared to an incidence of 3.8% among
older children. Butera et al14 observed minor complications in 3 patients under 1 year of age in a series of 18 symptomatic children under 3 years of age, all of whom had
undergone successful closure of PDA. Concordantly, the overall incidence of complications observed in our study was (12.8%), 4/28 patients (14.3%) in group A and 2/19
patients (10.5%) in group B, and all were minor in the form of mild loin hematoma in 5 cases in which a 6 Fr delivery sheath had been used and 1 case of venous
thrombosis treated with urokinase. These were managed successfully with no long-term sequelae.
Embolization or poor positioning of the device are rare.11,19,21 High-velocity residual leaks are also rare, which means that mechanical hemolysis is infrequent.25,26
Thrombus formation or the development of infective endocarditis have not been reported, although the administration of aspirin (5 mg/kg) and antibiotic prophylaxis was
recommended for 6 months.17
When comparing the advantages of the new ADO II with other Amplatzer occluders, Thanopoulos et al27 reported that its most important features were the low-profile
retention disks that can adapt to the dierent PDA insertion angles within the aorta and left pulmonary artery, thereby minimizing the risk of device-associated obstruction.
Conclusion
In this study, we conclude that percutaneous closure of moderate to large PDAs using ADO I and II devices in infants and children younger than 2 years of age is safe and
eective as evidenced by the low incidence of complications and residual shunt. Duct morphology, proper device selection, and masterful technique are mainstays for
success.
References
1. Porstmann W, Wierny L, Warnke H. Der Verschluss des Ductus Arteriosus persistens ohne Thorakotomie. Thoraxchirurgie. 1967;15(2):199-203.
2. Porstmann W, Wierny L, Warnke H, Gerstberger G, Romaniuk PA. Catheter closure of patent ductus arteriosus: sixty-two cases treated without thoracotomy. Radiol
Clin North Am. 1971;9(2):203-218.
3. Rashkind WJ, Cuaso CC. Transcatheter closure of a patent ductus arteriosus: successful use in a 3.5 kg infant. Pediatr Cardiol. 1979;1:3-7.
4. Lloyd TR, Fedderly R, Mendelshon AM, Sandhu SK, Beekman RH. Transcather occlusion of patent ductus arteriosus with Gianturco coils. Circulation. 1993;88(4 Pt
1):1412-1420
5. Podnar T, Masura J. Percutaneous closure of patent ductus arteriosus using special screwing detachable coils. J Cath Cardiovasc Diagn. 1997;41(4):386-391.
6. Grifka RG, Mullins CE, Gianturco C, et al. New Gianturco-Grifka vascular occlusion device. Initial studies in a canine model. Circulation. 1995;91(6):1840-1846.
7. Tometzki A, Redel DA, Wilson N. Total UK multicentre experience with a novel arterial occlusion device (Duct-Occlud). Heart. 1996;76(6):520-524.
8. Tometzki A, Arnold R, Peart I, et al. Transcatheter occlusion of the patent ductus arteriosus with Cook detachable coils. Heart. 1996;76(6):531-535.
9. Uzun O, Veldtman GR, Dickinson DF, Parson JM, Blackburn ME, Gibbs JL. Haemolysis following implantation of ductus occlusion coils. Heart. 1999;81(2):160-161.
10. Masura J, Walsh KP, Thanopoulous B, et al. Catheter closure of moderate- to large-sized patent ductus arteriosus using the new Amplatzer Duct Occluder: immediate
and short term results. J Am Coll Cardiol. 1998;31(4):878-882.
11. Bilkis AA, Alwi M, Hasri S, et al. The Amplatzer duct occluder: experience in 209 patients. J Am Coll Cardiol. 2001;37(1):258-261.
12. Faella H, Hijazi ZM. Closure of the patent ductus arteriosus with the amplatzer PDA device: immediate results of the international clinical trial. Cathet Cardiovasc
Intervent. 2000;51(1):50-54.
13. Fischer G, Stieh J, Uebing A, Grabitz R, Kramer HH. Transcatheter closure of patent ductus arteriosus in infants using Amplatzer duct occluder. Heart.
2001;86(4):444-447.
14. Butera G, De Rosa G, Chessa M, et al. Transcatheter closure of persistent duct arteriosus with the Amplatzer duct occluder in very young symptomatic children.
Heart. 2004;90(12):1467-1470.
15. Ramos-Galvan R. The significance and use of somatometric reference values of weight and height in pediatric and epidemiologic practice. Bol Med Hosp Infant Mex.
1992;49(6):321-334.
16. Krichenko A, Benson LN, Burrows P, Mes CA, McLaughlin P, Freedom RM. Angiographic classification of the isolated, persistently patent ductus arteriosus and
implications for percutaneous catheter occlusion. Am J Cardiol. 1989;63(12):877-880.
17. Thanopoulos BD, Hakim FA, Hiari A, et al. Further experience with transcatheter closure of the patent ductus arteriosus using the Amplatzer duct occluder. J Am Coll
Cardiol. 2000;35(4):1016-1021.
18. Masura J, Tittel P, Gavora P, Podnar T. Long-term outcome of transcatheter patent ductus arteriosus closure using Amplatzer duct occluders. Am Heart J.
2006;151(3):755.e7-e10.
19. Fernndez A, del Cerro MJ, Rubio D, Castro MC, Moreno F. Cierre percutneo del ductus arterioso persistente con dispositivo de Amplatz: resultado inmediato y
seguimiento a medio plazo. Rev Esp Cardiol. 2002;55(10):1057-1062.
20. Sandhu SK, King TD, Troutman WB, Hixon RL 3rd, Kiel EA, Bourgeois KV. Transcatheter closure of patent ductus arteriosus with the Amplatzer duct occluder: shortterm follow-up. J Invasive Cardiol. 2001;13(4):298-302.
21. Al-Ata J, Arfi A, Hussain A, Kouatli A, Jalal O. The ecacy and safety of the Amplatzer ductal occluder in young children and infants. Cardiol Young. 2005:15(3):279285.
22. Roberts P, Adwani S, Archer N, Wilson N. Catheter closure of the arterial duct in preterm infants. Arch Dis Child Fetal Neo. 2007;92(4):F248-E250.
23. Galal O, Bulbul Z, Kakadekar A, et al. Comparison between the safety profile and clinical results of cook detachable and Gianturco coils for transcatheter closure of
the patent ductus arteriosus in 272 patients. J Intervent Cardiol. 2001;14(2):169-178.
24. Duke C, Chan KC. Aortic obstruction caused by device occlusion of patent arterial duct. Heart. 1999;82(1):109-111.
25. Godart F, Rods J, Rey C. Severe haemolysis after transcatheter closure of a patent arterial duct with the new Amplatzer duct occluder. Cardiol Young.
2000;10(3):265-267.
26. Wang JK, Wu MH, Hwang JJ, Chiang FT, Lin MT, Lue HC. Transcatheter closure of moderate to large PDA with Amplatzer duct occluder. Catheter Cardiovasc Interv.
2007;69(4):572-578.
27. Thanopoulos B, Eleftherakis N, Tzannos K, Stefanadis C. Transcatheter closure of the patent ductus arteriosus using the new Amplatzer duct occluder: initial clinical
applications in children. Am Heart J. 2008;156:917.e1-e6.
______________________________________________
From the Department of Pediatrics, Faculty of Medicine, Cairo University, Cairo, Egypt.
Disclosure: The authors have completed and returned the ICMJE Form for Disclosure of Potential Conflicts of Interest. The authors report no conflicts of interest regarding
the content herein.
Manuscript submitted March 13, 2012, provisional acceptance given March 27, 2012, final version accepted May 4, 2012.
Address of correspondence: Ranya A Hegazy, MD, Assistant Professor of Pediatrics, Faculty of Medicine, Cairo University, 3 Ramez St. o Shehab St, Mohandeseen, Giza,
Egypt. Email: r_hegazy@hotmail.com (mailto:r_hegazy@hotmail.com)
Add new comment

Your name
E-mail
Homepage
Comment *
What code is in the image? *
Save
Preview
Search JIC
Search
zid=18&cid=882&mid=880&pid=0&sid=8&uuid=9e8924e9b27e3e60b4b9b7103f27fd8a&ip=36.76.158.152&default=false&random=63120906&timestamp=20150707053135&test=
closure-medium-and-large-pdas-using-amplatzer-duct-occluder-ado-i-and-ii&redirect=http%3A%2F%2Fwww.invasivecardiology.com%2Fsudden-cardiac-death)
zid=93&cid=1604&mid=1591&pid=0&sid=8&uuid=9e8924e9b27e3e60b4b9b7103f27fd8a&ip=36.76.158.152&default=false&random=18238188&timestamp=20150707053135&tes
closure-medium-and-large-pdas-using-amplatzer-duct-occluder-ado-i-and-ii&redirect=http%3A%2F%2Ftinyurl.com%2FCLDTirofiban)
zid=93&cid=1604&mid=1591&pid=0&sid=8&uuid=cfbe2f1b82dc92754730425cd758321f&ip=36.76.158.152&default=false&random=99135106&timestamp=20150707052541&tes
zid=93&cid=1604&mid=1591&pid=0&sid=8&uuid=cfbe2f1b82dc92754730425cd758321f&ip=36.76.158.152&default=false&random=99135106&timestamp=20150707052541&tes
Most Popular Articles

1. Hemodynamic Eects of Standard Versus Larger-Capacity Intraaortic Balloon Counterpulsation Pumps (/articles/hemodynamic-eects-standard-versuslarger-capacity-intraaortic-balloon-counterpulsation)
2. A Comparative Study of Defibrillator Leads at a Large-Volume Implanting Hospital: Results From the Pacemaker and Implantable Defibrillator Leads Survival
Study (PAIDLESS) (/articles/comparative-study-defibrillator-leads-large-volume-implanting-hospital-results-pacemaker)

3. Clinical Outcomes in the Percutaneous Coronary Intervention of In-Stent Restenosis With Everolimus-Eluting Stents (/articles/clinical-outcomespercutaneous-coronary-intervention-stent-restenosis-everolimus-eluting)
4. Correlation Between Markers of Reperfusion and Mortality in ST-Elevation Myocardial Infarction: A Systematic Review (/articles/correlation-betweenmarkers-reperfusion-and-mortality-st-elevation-myocardial-infarction)
5. Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy: Safe and Apparently Ecacious But Does Reporting of Aggregate Outcomes Hide
Less-Favorable Results, Experienced by a Substantial Proportion of Patients? (/articles/alcohol-septal-ablation-hypertrophic-obstructive-cardiomyopathysafe-and-apparently)
6. Inappropriate Use of the Appropriate Use Criteria (AUC) as a Guide for Reimbursement (/articles/inappropriate-use-appropriate-use-criteria-auc-guidereimbursement)
7. Tips and Tricks for Antegrade Recanalization of Chronic Total Occlusions Using the CrossBoss Catheter (/articles/tips-and-tricks-antegrade-recanalizationchronic-total-occlusions-using-crossboss-catheter)
8. Coronary Artery Bypass Surgery Compared With Percutaneous Coronary Intervention for Proximal Left Anterior Descending Artery Treatment in Patients With
Acute Coronary Syndrome: Analysis From the ACUITY Trial (/node/5864)
View More (/popular)
zid=127&cid=1312&mid=1320&pid=0&sid=8&uuid=9e8924e9b27e3e60b4b9b7103f27fd8a&ip=36.76.158.152&default=false&random=58293093&timestamp=20150707053136&
closure-medium-and-large-pdas-using-amplatzer-duct-occluder-ado-i-and-ii&redirect=http%3A%2F%2Fcathlablive.com%2FMetroLive)
zid=127&cid=1312&mid=1320&pid=0&sid=8&uuid=cfbe2f1b82dc92754730425cd758321f&ip=36.76.158.152&default=false&random=62709640&timestamp=20150707052542&
Blog
View More (/blog)

SCAD in Women (/blog/scad-women)
More on PAIDLESS (/blog/more-%E2%80%9Cpaidless%E2%80%9D)
Journal of Invasive Cardiology Launches Ahead of Print Section (/blog/journal-invasive-cardiology-launches-ahead-print-section)
IABP and pVADs: Clinical Eectiveness Versus Cost (/blog/iabp-and-pvads-clinical-eectiveness-versus-cost)
Event Calendar
View More (/events)
SCCT 2015 Annual Scientific Meeting -- Society of Cardiovascular Computed Tomography (/events/scct-2015-annual-scientific-meeting-society-cardiovascular-computed-tomography)
July 16, 2015
July 19, 2015
Las Vegas, United States
5th Annual AMP Symposium (/events/5th-annual-amp-symposium)

August 12, 2015
August 15, 2015
United States
ESC Congress 2015 European Society of Cardiology (/events/esc-congress-2015-%E2%80%93-european-society-cardiology)

August 29, 2015
September 2, 2015
United Kingdom
PICS-AICS: Pediatric and Adult Interventional Cardiac Symposium (/events/pics-aics-pediatric-and-adult-interventional-cardiac-symposium-0)

September 18, 2015
September 21, 2015
Las Vegas, United States
TCT 2015 Transcatheter Cardiovascular Therapeutics (/events/tct-2015-%E2%80%93-transcatheter-cardiovascular-therapeutics)

October 11, 2015
October 15, 2015
San Francisco, United States
zid=128&cid=1622&mid=1610&pid=0&sid=23&uuid=9e8924e9b27e3e60b4b9b7103f27fd8a&ip=36.76.158.152&default=false&random=81901215&timestamp=20150707053136
closure-medium-and-large-pdas-using-amplatzer-duct-occluder-ado-i-and-ii&redirect=http%3A%2F%2Fwww.cathlablive.com%2Fcontent%2Fcme-video-registration)
Back to top
Subscribe
Renew
(/print_subscriptions) (/print_subscriptions)
Reprints
Advertise
(/Reprints-Rights(/Advertise)
PermissionTranslation)
Permissions
(/Advertise)
SOCIAL
Twitter (https://twitter.com/InvasiveCardiol)
Facebook (https://www.facebook.com/pages/Journal-of-Invasive-Cardiology/158043632915)
Linkedin (http://www.linkedin.com/groups/Journal-Invasive-Cardiology-2438755?home=&gid=2438755&trk=anet_ug_hm)
E-NEWS
Get the latest JIC news and TOC alerts straight to your email.
SIGN UP (/e-news)
EDITORIAL INFO
ISSN Print 1042-3931 / Electronic 1557-2501
Impact Factor: 0.824
Editorial Board (/content/journal-invasive-cardiology-editorial-board)
Contact (/contact)
Please visit our other brands:

Vascular Disease Management (http://www.vasculardiseasemanagement.com/)
Cath Lab Digest (http://www.cathlabdigest.com/)
EP Lab Digest (http://www.eplabdigest.com/)
About Us
Contact Us
Home
Other Publications
Privacy Policy
HMP Communications LLC (HMP) is the authoritative source for comprehensive information and education servicing health care professionals. HMPs products include
peer-reviewed and non-peer-reviewed medical journals, national tradeshows and conferences, online programs and customized clinical programs. HMP is a wholly owned
subsidiary of HMP Communications Holdings LLC. 2015 HMP Communications

Percutaneous Closure of Medium and Large PDAs Using Amplatzer Duct Occluder (ADO) I and II in Infant

Загружено:

Сведения о документе

Авторское право

Доступные форматы

Поделиться этим документом

Поделиться или встроить документ

Параметры публикации

Этот документ был вам полезен?

Это неприемлемый материал?

Авторское право:

Доступные форматы

Percutaneous Closure of Medium and Large PDAs Using Amplatzer Duct Occluder (ADO) I and II in Infant

Загружено:

Авторское право:

Доступные форматы

(/)

Author(s): Rasha I. Ammar, MD and Ranya A. Hegazy, MD

Add new comment

What code is in the image? *

Most Popular Articles

Study (PAIDLESS) (/articles/comparative-study-defibrillator-leads-large-volume-implanting-hospital-results-pacemaker)

View More (/blog)

More on PAIDLESS (/blog/more-%E2%80%9Cpaidless%E2%80%9D)

Journal of Invasive Cardiology Launches Ahead of Print Section (/blog/journal-invasive-cardiology-launches-ahead-print-section)

IABP and pVADs: Clinical Eectiveness Versus Cost (/blog/iabp-and-pvads-clinical-eectiveness-versus-cost)

View More (/events)

July 19, 2015

Las Vegas, United States

5th Annual AMP Symposium (/events/5th-annual-amp-symposium)

August 15, 2015

ESC Congress 2015 European Society of Cardiology (/events/esc-congress-2015-%E2%80%93-european-society-cardiology)

PICS-AICS: Pediatric and Adult Interventional Cardiac Symposium (/events/pics-aics-pediatric-and-adult-interventional-cardiac-symposium-0)

September 21, 2015

Las Vegas, United States

TCT 2015 Transcatheter Cardiovascular Therapeutics (/events/tct-2015-%E2%80%93-transcatheter-cardiovascular-therapeutics)

October 15, 2015

San Francisco, United States

Please visit our other brands:

Вам также может понравиться